--The business combination of two AI-powered drug discovery and development companies, Recursion and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion ...

As Pipeline Advances, Recursion Expands AI Focus to Clinical Trials Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge the company aims to improve design of studies, accelerate ...

Algorithm design and analysis is fundamental to all areas of computer science and gives a rigorous framework for the study optimization. This course provides an introduction to algorithm design ...

Recursion Halts Four Pipeline Programs, Sharpening Cancer, Rare Disease Focus AI drug developer advances fourth Sanofi-partnered program, earns $7M milestone payment ...

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform ...